Alpine Immune Sciences Inc (ALPN) Expected to Post Earnings of -$0.62 Per Share

Brokerages forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will announce earnings per share (EPS) of ($0.62) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.48). Alpine Immune Sciences posted earnings of ($0.38) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 63.2%. The business is scheduled to announce its next quarterly earnings report on Monday, May 13th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.71) per share for the current year, with EPS estimates ranging from ($3.68) to ($2.10). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.45) to ($1.84). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.80) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.80).

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. ValuEngine cut Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Friday, January 11th. Finally, restated a “buy” rating and issued a $13.00 price objective on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $12.07.

In other Alpine Immune Sciences news, Director James N. Topper purchased 372,439 shares of Alpine Immune Sciences stock in a transaction that occurred on Friday, January 18th. The stock was acquired at an average price of $5.37 per share, for a total transaction of $1,999,997.43. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tiger Management L.L.C. sold 25,000 shares of Alpine Immune Sciences stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The disclosure for this sale can be found here. 69.00% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. grew its holdings in shares of Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock valued at $501,000 after buying an additional 70,980 shares in the last quarter. Hikari Power Ltd purchased a new position in shares of Alpine Immune Sciences during the fourth quarter valued at $453,000. Vanguard Group Inc grew its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 11,200 shares in the last quarter. Institutional investors and hedge funds own 53.79% of the company’s stock.

Shares of NASDAQ ALPN opened at $7.40 on Friday. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a fifty-two week low of $3.66 and a fifty-two week high of $10.57.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: How to read a candlestick chart

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit